UPDATE: Antibiotic Resistance Meets Financial Crime Networks Our previous analysis of antibiotic resistance patterns since Fleming's discovery now intersects with emerging 2026 financial crime projections—specifically how AI-enabled fraud and sanctions evasion schemes are targeting pharmaceutical supply chains. Criminal networks are increasingly exploiting gaps in drug authentication and distribution networks in developing regions, exacerbating antibiotic misuse where counterfeit medications drive resistance. This convergence represents a critical blind spot: while we track biological resistance patterns historically, coordinated financial crime and virtual asset flows are actively undermining the regulatory infrastructure meant to control antibiotic access globally.